FDA Should Regulate Biologic Generics: FTC Report

Law360, New York (June 10, 2009, 12:00 AM EDT) -- Giving the U.S. Food and Drug Administration the authority to approve generic versions of biologic drugs would be an effective way to cut costs for the pricey treatments and introduce competition into the biologics market, a report released Wednesday by the Federal Trade Commission said.

In the report, the FTC weighed in on the growing debate over the best way to bring generic versions of biologic drugs — known as follow-on-biologics, or FOBs — to consumers.

Biologic drugs are produced from living cell cultures rather than...
To view the full article, register now.